

anti-inflammatoxy and immuno-therapy - all results

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
Immunostimulants drugs	21 studies ¹	demonstrated 64			
anti-inflammatory therapies	2 studies ²		inconclusive results for : death D28 ; deaths ; hospitalization or death ; hospitalization ; mechanical ventilation ; recovery ; related AE (TRAE) ; serious adverse events		
corticosteroids	2 studies ³		inconclusive results for : death D28 ; deaths ; hospitalization or death ; clinical improvement (14-day) ; clinical improvement (28-day) ; clinical improvement (7-day) ; hospitalization ; recovery ; adverse events		
inhaled corticosteroids	2 studies ⁴	demonstrated 21			

Uncertain results are statistically significant results but obtain in trial with high risk of bias.

Demonstrated results are significant results obtained on the primary endpoint of a trial at low risk of bias or with some concerns.

Notes

¹ACTIV-2 SNG001, 2022 (NCT04518410) ; CoV-Early (Gharbharan), 2022 (NCT04589949) ; TOGETHER interferon lambda, 2022 (NCT04727424) ; BLAZE-1 phase 3 (combo), 2021 (NCT04427501) ; COMET-ICE, 2021 (NCT04545060) ; CONV-ERT, 2021 (NCT04621123) ; Cov-2069 (Cohort B : positive SARS-CoV-2 RT-qPCR test result), 2021 (NCT04452318) ; CT-P59 3.2 part 1, 2021 (NCT04602000) ; CT-P59 3.2 part 2, 2021 (NCT04602000) ; Feld, 2021 (NCT04354259) ; OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021 (NCT04790786) ; BLAZE-1 phase 2 (combination with etesevimab), 2020 (NCT04427501) ; BLAZE-1 phase 2 (monotherapy), 2020 (NCT04427501) ; C3PO, 2020 (NCT04355767) ; Cov-2067 Weinreich (1200mg) Cohort 1, 2020 (NCT04425629) ; ACTIV-2 (BRIL-196 and BRIL-198), 0 (NCT04518410) ; BLAZE 4 LY-CoV1404, 0 (NCT04634409) ; BLAZE-4, 0 (NCT04634409) ; TACKLE, 0 (NCT04723394) ; Bariola, 2021 ()

²COLCORONA, 2021 (NCT04322682) ; PRINCIPLE (COLCHICINE), 2021 (ISRCTN86534580)

³Clemency, 2021 (NCT04377711) ; Ezer N (CONTAIN), 2021 (NCT04435795)

⁴PRINCIPLE, 2021 (ISRCTN86534580) ; STOIC, 2021 (NCT04416399)